---
schema_version: "secwatch.filing_event.v1"
accession: "0001453687-24-000108"
form_type: "8-K"
ticker: "RNAC"
cik: "0001453687"
company_name: "Cartesian Therapeutics, Inc."
filed_at: "2024-09-23T23:59:59+00:00"
generated_at: "2026-05-31T02:22:04.081898+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.1
calibrated_materiality_score: 0.1
confidence: "high"
source: SEC EDGAR
---

# Stockholders approve conversion of Series B Preferred at special meeting

## Summary
- Special meeting held Sep 20, 2024; 75.9% of outstanding shares represented.
- Proposal 1 passed: 12,514,261 FOR, 150,060 AGAINST, 1,650 abstentions (excluding 3,563,247 shares for Nasdaq compliance).
- Proposal 2 (adjournment if needed) approved: 16,076,183 FOR, 151,789 AGAINST, 1,246 abstentions.
- Approval allows issuance of common stock upon conversion of Series B Non-Voting Convertible Preferred.

## SEC filing metadata
- accession: 0001453687-24-000108
- form_type: 8-K
- ticker: RNAC
- cik: 0001453687
- company_name: Cartesian Therapeutics, Inc.
- filed_at: 2024-09-23T23:59:59+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.1
- calibrated_materiality_score: 0.1
- confidence: high
- sec_items: 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1453687/000145368724000108/0001453687-24-000108-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1453687/000145368724000108/rnac-20240920.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001453687-24-000108
- JSON: https://secwatch.observer/filing/0001453687-24-000108.json
- Plain text: https://secwatch.observer/filing/0001453687-24-000108.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.